• Paclitaxel Sensitizer Discovery in Glioblastoma via HTS of F

  2026-04-29

  Wei et al. used high-throughput screening of 1,001 FDA-approved compounds to identify 37 drugs that enhance paclitaxel sensitivity in glioblastoma cells, including four not previously linked to GBM therapy. These findings suggest actionable avenues for drug repositioning and combinatorial chemotherapy in difficult-to-treat brain cancers.

• Methicillin Sodium Salt: Precision Tools for Translational M

  2026-04-28

  This thought-leadership article examines Methicillin sodium salt as a cornerstone for translational infection models, providing mechanistic depth and actionable guidance for researchers. It integrates state-of-the-art screening paradigms, protocol optimization, and competitive insights—anchored by evidence and strategic context—to empower the next generation of Staphylococcus aureus infection studies.

• 7ACC2: A Potent Monocarboxylate Transporter 1 Inhibitor for

  2026-04-28

  7ACC2 is a highly potent monocarboxylate transporter 1 inhibitor that impedes lactate uptake and mitochondrial pyruvate transport in cancer cells. Its nanomolar efficacy and dual mechanism make it a valuable tool for cancer metabolism research and tumor growth delay. APExBIO supplies 7ACC2 (SKU B4868) for laboratory use with validated pharmacokinetic benchmarks.

• SP1/ADAM10/DRP1 Axis Regulates Vascular Remodeling in HPH

  2026-04-27

  This study elucidates the SP1/ADAM10/DRP1 signaling axis as a central mediator of endothelial–smooth muscle cell communication under hypoxic conditions relevant to pulmonary hypertension. By dissecting both molecular mechanisms and intercellular signaling, the research identifies actionable targets for modulating vascular remodeling and suggests new directions for mitochondrial dynamics research.

• HR Gene Expression Predicts Olaparib Response in Mesotheliom

  2026-04-27

  Borchert et al. (2019) demonstrate that homologous recombination repair (HRR) gene expression profiling, particularly BRCAness features and BAP1 mutations, predicts susceptibility to olaparib treatment in malignant pleural mesothelioma (MPM) cell lines. These findings suggest a rationale for stratifying MPM patients for PARP inhibitor-based therapies and offer new biomarkers for prognosis and therapeutic decision-making.

• 2-NBDG in Translational Glucose Metabolism: Mechanistic and

  2026-04-26

  This thought-leadership article explores the mechanistic underpinnings and strategic applications of 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) as a fluorescent glucose analog. By integrating evidence from recent translational studies, including novel insights into gestational diabetes and the PCSK9/LDLR axis, the article provides actionable guidance for metabolic researchers. We highlight best practices, competitive advantages, and translational opportunities that elevate the utility of APExBIO's 2-NBDG beyond standard product guides.

• Tiamulin (Thiamutilin): Precision Modulation of Inflammatory

  2026-04-25

  Explore the advanced mechanisms of Tiamulin (Thiamutilin), a veterinary antibiotic, in modulating TNF-α and NF-κB signaling. This article uniquely dissects its dual antibacterial and anti-inflammatory roles, bridging evidence from cutting-edge dermatological research to practical assay optimization.

• Cholesterol Impedes Lipid Nanoparticle Trafficking for Nucle

  2026-04-24

  Luo et al. reveal that elevated cholesterol in lipid nanoparticles (LNPs) significantly restricts intracellular trafficking and delivery efficiency of nucleic acid cargos by promoting their retention in peripheral early endosomes. This study highlights cholesterol's unexpected detrimental role and provides actionable insights for optimizing LNP formulations in gene therapy and mRNA vaccine design.

• Chlorpromazine HCl: Advanced Dopamine Antagonism in Endocyto

  2026-04-24

  Explore the multifaceted role of Chlorpromazine HCl as a dopamine receptor antagonist in endocytosis and neuropharmacology studies. This article uniquely integrates mechanistic insights, protocol parameters, and evidence-based guidance for experimental design.

• AT13387 and Precision Hsp90 Inhibition: Catalyzing Translati

  2026-04-23

  This thought-leadership article explores how AT13387, a next-generation orally bioavailable Hsp90 inhibitor, is reshaping cancer biology research. Blending mechanistic insights with strategic guidance, we examine the scientific rationale for targeting Hsp90, recent advances in understanding apoptosis—including the role of NINJ1 in cell death and DAMP release—and competitive advantages of AT13387 for translational workflows. We highlight experimental benchmarks, protocol parameters, and the broader translational landscape, offering actionable direction for researchers striving for innovation in oncology.

• FCCP: Applied Use-Cases in Mitochondrial Biology Research

  2026-04-23

  FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) is a benchmark tool for dissecting mitochondrial function and hypoxia signaling in cancer and immunometabolic research. This guide delivers actionable workflows, troubleshooting insights, and protocols tailored for high-impact studies leveraging APExBIO’s FCCP.

• Ribociclib Succinate (LEE011): Advanced pH-Resilient CDK Inh

  2026-04-22

  Explore the unique pH-resilient properties of Ribociclib succinate, a leading CDK inhibitor for cancer research. This article delivers technical depth, practical assay guidance, and actionable insights for optimizing antineoplastic workflows.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu

  2026-04-22

  This study introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, offering a physiologically relevant in vitro model for pharmacokinetic research. The approach enables robust assessment of human-specific drug metabolism, specifically for cytochrome P450 enzymes such as CYP2C19, with potential to advance preclinical evaluation of orally administered drugs.

• Vascular Effects of JAK Inhibitors on Endothelial Inflammati

  2026-04-21

  This article examines recent findings on how different JAK inhibitors, including tofacitinib citrate (CP-690550 citrate), affect endothelial cell dysfunction and prothrombotic signaling during inflammatory cytokine exposure. The study highlights nuanced differences in cytokine modulation and cardiovascular safety, offering insights for immune regulation and inflammatory disorder research.

• Sumatriptan Succinate: Advanced 5-HT1 Receptor Agonist Workf

  2026-04-21

  Sumatriptan Succinate is redefining migraine and neuroinflammation research as a selective 5-HT1 receptor agonist. This guide delivers optimized experimental protocols, actionable troubleshooting, and practical insights that maximize reproducibility and translational impact across serotonergic signaling paradigms.

421 records 18/29 page Previous Next First page 上5页 1617181920 下5页 Last page